secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001285550-22-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance
----------------------------------------------------------------------------

- Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.
- Partner PTC Therapeutics received EU marketing authorization for Upstaza; uses ClearPoint SmartFlow Neuro Cannula.
- Reaffirmed FY2022 revenue guidance of $21-22M.
- Cash and short-term investments $45.1M at June 30, 2022.
- Added >45 partners; installed 8 systems YTD (4 in Q2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/0001285550-22-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/clpt-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001285550-22-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer